Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Silence Therapeutics (SLN) EBT Margin: 2019-2024

Historic EBT Margin for Silence Therapeutics (SLN) over the last 6 years, with Dec 2024 value amounting to 102.79%.

  • Silence Therapeutics' EBT Margin fell 1081101.00% to 13,180.50% in Q3 2025 from the same period last year, while for Sep 2025 it was 248.57%, marking a year-over-year increase of 17274.00%. This contributed to the annual value of 102.79% for FY2024, which is 6557.00% up from last year.
  • As of FY2024, Silence Therapeutics' EBT Margin stood at 102.79%, which was up 38.95% from 168.35% recorded in FY2023.
  • Over the past 5 years, Silence Therapeutics' EBT Margin peaked at 102.79% during FY2024, and registered a low of 657.80% during FY2020.
  • Its 3-year average for EBT Margin is 180.62%, with a median of 168.35% in 2023.
  • Its EBT Margin has fluctuated over the past 5 years, first skyrocketed by 871,515bps in 2020, then crashed by 6,557bps in 2024.
  • Over the past 5 years, Silence Therapeutics' EBT Margin (MRY) stood at 657.80% in 2020, then skyrocketed by 44bps to 369.36% in 2021, then rose by 27bps to 270.71% in 2022, then soared by 38bps to 168.35% in 2023, then surged by 39bps to 102.79% in 2024.
  • Its EBT Margin stands at 102.79% for FY2024, versus 168.35% for FY2023 and 270.71% for FY2022.